Research Update

Phytopharm PLC
15 November 2005


Company Contact:                                 U.K. Investor relations contact
Phytopharm, plc                                  Financial Dynamics
Richard Dixey                                    David Yates/Ben Atwell
[phone]                                  [phone]
www.phytopharm.com




                                 PHYTOPHARM PLC

                             Clinical trial results


GODMANCHESTER, Cambridgeshire, U.K. (15 November, 2005) - Phytopharm plc (LSE:
PYM; NASDAQBB: PHYOF; PHYOY) ('Phytopharm') has become aware of rumours
circulating that the results of the phase II double blind placebo controlled
study on CoganeTM, Phytopharm's treatment for mild to moderate Alzheimer's
disease, are known to the Company.

Following advice received from the London Stock Exchange, Phytopharm wishes to
make clear that it has no such information, and that the preliminary results of
this study will not be available to the Company until early December 2005, at
which time they will be promptly announced to the stock market.


                                    - Ends -


                      This information is provided by RNS
            The company news service from the London Stock Exchange              FELSFFE